Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

16 Mar 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Fri, Dec 29 2017

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Chugai Pharmaceutical says change of chief executive officer

* Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I

Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo

ZURICH, Nov 14 Chugai Pharmaceuticals, a Japan-based Roche subsidiary, said on Tuesday it has agreed to transfer the marketing and manufacturing right of 13 long-term listed products to Taiyo Holdings' Taiyo Pharma.

BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma

* Says it and TAIYO HOLDINGS CO LTD announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings

BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei

* Chugai Pharma considering selling production, sales rights of some 15 medications with expired patents to Taiyo Holdings for about 20 billion yen - Nikkei Source text : (http://s.nikkei.com/2iRwewI) Further company coverage:

Select another date: